SG11201805913QA - New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents
New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- SG11201805913QA SG11201805913QA SG11201805913QA SG11201805913QA SG11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- utca
- berkshire
- budapest
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111011101110110111 HO HAIM III International Bureau ... ...... .Y1 j (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/125224 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: BALINT, Balizs; Lehel utca 18, 2151 Hit (HU). SIPOS, C07F 9/6561 (2006.01) A61K 31/519 (2006.01) Szabolcs; Roppentyil utca 21-23., A epillet 3/10, H-1139 A61P 35/00 (2006.01) C07D 495/04 (2006.01) Budapest (HU). A61K 31/661 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2016/081688 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (22) International Filing Date: DO, 19 December 2016 (19.12.2016) HN, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (26) Publication Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 16/50411 19 January 2016 (19.01.2016) FR TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicants: LES LABORATOIRES SERVIER [FR/FR]; 35 me de Verdun, 92284 Suresnes (FR). VER- (84) Designated States (unless otherwise indicated, for every NALIS (R&D) LIMITED [GB/GB]; 100 Berkshire Place, kind of regional protection available): ARIPO (BW, GH, Wharfedale Road, Berkshire, Winnersh Berkshire RG41 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 5RD (GB). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, — (72) Inventors: PACZAL, Attila; Orjarat utca 95., H-1158 DK, EE, ES, FI, FR, GB, GR, HR, HU, IF, IS, IT, LT, LU, — _ Budapest (HU). SZLAVIK, Zoltan; Kolto utca 2-4 D/2, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, = 1121 Budapest (HU). KOTSCHY, Andras; Almos Vezer SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, u.4, 2045 Torokbalint (HU). CHANRION, Maya; 14 rue GW, KM, ML, MR, NE, SN, TD, TG). = de la Galiote, Apt D441, 92130 Issy Les Moulineaux (FR). MARAGNO, Ana Leticia; 4, Allee Anastasi, 78290 Published: Croissy-sur-Seine (FR). GENESTE, Olivier; Batiment A, — with international search report (Art. 21(3)) = 17, rue Crevel Duval, 92500 Rueil Malmaison (FR). DE- = MARLES, Didier; 21 me du Lievre, 45430 Checy (FR). = (54) Title: NEW AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COM- _ = POSITIONS CONTAINING THEM = = H 3 C, , 0 N ---.-- \"* . = = I N i -: \" . '\"--,, = 1 0 = 0 - e ll R 3 R Z (I) 11 O R 4 • ii- ei ei kin ei ,-1 Y O Rl • IN ,-1 0 (57) : Compounds of formula (I): wherein R I , R, R 2 3 , R 4 , R 5 , R 6 and ei Y are as defined in the description. Medicaments. 0
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1650411A FR3046792B1 (en) | 2016-01-19 | 2016-01-19 | NOVEL AMMONIUM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| PCT/EP2016/081688 WO2017125224A1 (en) | 2016-01-19 | 2016-12-19 | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805913QA true SG11201805913QA (en) | 2018-08-30 |
Family
ID=55752504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805913QA SG11201805913QA (en) | 2016-01-19 | 2016-12-19 | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them |
Country Status (43)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3037958B1 (en) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR3037956B1 (en) * | 2015-06-23 | 2017-08-04 | Servier Lab | NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| AU2018205735B2 (en) * | 2017-01-06 | 2024-02-01 | Les Laboratoires Servier | Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof |
| UY37560A (en) | 2017-01-06 | 2018-07-31 | Servier Lab | COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS |
| WO2018234433A1 (en) | 2017-06-22 | 2018-12-27 | Les Laboratoires Servier | Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof |
| UY37843A (en) | 2017-08-15 | 2019-03-29 | Abbvie Inc | MCL-1 MACROCYCLIC INHIBITORS AND METHODS OF USE |
| WO2019035927A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| UY37842A (en) * | 2017-08-15 | 2019-03-29 | Abbvie Inc | MCL-1 MACROCYCLIC INHIBITORS AND METHODS OF USE |
| CN108424417B (en) * | 2017-12-21 | 2019-09-20 | 河南真实生物科技有限公司 | Thienopyrimidine derivative, preparation method and application in preparation of anti-tumor drugs |
| AR116635A1 (en) | 2018-10-15 | 2021-05-26 | Servier Lab | PROCESS FOR THE SYNTHESIS OF PIPERAZINIL-ETOXY-BROMOPHENIL DERIVATIVES AND THEIR APPLICATION IN THE PRODUCTION OF COMPOUNDS CONTAINING THEM |
| TW202038960A (en) | 2018-11-14 | 2020-11-01 | 法商施維雅藥廠 | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof |
| BR112021010072A2 (en) * | 2018-12-06 | 2021-08-24 | Les Laboratoires Servier | Crystalline forms of an mcl-1 inhibitor, process for their preparation and pharmaceutical compositions containing them |
| WO2020236825A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2020254299A1 (en) | 2019-06-17 | 2020-12-24 | Les Laboratoires Servier | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof |
| KR20220099125A (en) * | 2019-10-03 | 2022-07-12 | 캘리포니아 인스티튜트 오브 테크놀로지 | MCL1 inhibitors and uses thereof |
| US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2022216946A1 (en) * | 2021-04-07 | 2022-10-13 | California Institute Of Technology | Mcl1 inhibitors and uses thereof |
| US11957693B2 (en) | 2021-06-11 | 2024-04-16 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-cancer agents |
| TW202317200A (en) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Combination mcl-1 inhibitors with anti-body drug conjugates |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650425A (en) * | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
| AU746007B2 (en) * | 1997-02-09 | 2002-04-11 | Pharmos Corporation | Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones |
| JP2008505084A (en) * | 2004-06-29 | 2008-02-21 | アムゲン インコーポレイティッド | Furanopyrimidine |
| EP2212333A1 (en) * | 2007-10-16 | 2010-08-04 | Wyeth LLC | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| DK2276346T3 (en) * | 2008-04-30 | 2017-02-27 | Nat Health Research Institutes | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS |
| TWI385174B (en) * | 2008-11-10 | 2013-02-11 | Nat Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| CN102464667B (en) * | 2010-11-03 | 2014-06-04 | 中国科学院上海药物研究所 | Five-membered heterocycle pyrimidine compounds, preparation method and application thereof |
| CN105209461A (en) * | 2012-11-14 | 2015-12-30 | 霍夫曼-拉罗奇有限公司 | Imidazopyridine derivatives |
| KR20210145303A (en) * | 2013-05-02 | 2021-12-01 | 에프. 호프만-라 로슈 아게 | Purine derivatives as cb2 receptor agonists |
| FR3015483B1 (en) * | 2013-12-23 | 2016-01-01 | Servier Lab | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
-
2016
- 2016-01-19 FR FR1650411A patent/FR3046792B1/en not_active Expired - Fee Related
- 2016-12-19 ME MEP-2019-336A patent/ME03555B/en unknown
- 2016-12-19 US US16/069,891 patent/US10457689B2/en active Active
- 2016-12-19 TN TNP/2018/000239A patent/TN2018000239A1/en unknown
- 2016-12-19 MD MDE20181134T patent/MD3405471T2/en unknown
- 2016-12-19 MA MA43639A patent/MA43639B1/en unknown
- 2016-12-19 MY MYPI2018702472A patent/MY196352A/en unknown
- 2016-12-19 JP JP2018555822A patent/JP6871275B2/en active Active
- 2016-12-19 SI SI201630558T patent/SI3405471T1/en unknown
- 2016-12-19 BR BR112018014536-0A patent/BR112018014536B1/en active IP Right Grant
- 2016-12-19 CA CA3011761A patent/CA3011761C/en active Active
- 2016-12-19 ES ES16816667T patent/ES2760545T3/en active Active
- 2016-12-19 PE PE2018001293A patent/PE20190336A1/en unknown
- 2016-12-19 SG SG11201805913QA patent/SG11201805913QA/en unknown
- 2016-12-19 AU AU2016387870A patent/AU2016387870B2/en active Active
- 2016-12-19 WO PCT/EP2016/081688 patent/WO2017125224A1/en active Application Filing
- 2016-12-19 MX MX2018008808A patent/MX2018008808A/en active IP Right Grant
- 2016-12-19 LT LT16816667T patent/LT3405471T/en unknown
- 2016-12-19 CR CR20180363A patent/CR20180363A/en unknown
- 2016-12-19 CU CU2018000073A patent/CU20180073A7/en unknown
- 2016-12-19 KR KR1020187023819A patent/KR20180098677A/en unknown
- 2016-12-19 EP EP16816667.6A patent/EP3405471B1/en active Active
- 2016-12-19 PL PL16816667T patent/PL3405471T3/en unknown
- 2016-12-19 PT PT168166676T patent/PT3405471T/en unknown
- 2016-12-19 HU HUE16816667A patent/HUE048449T2/en unknown
- 2016-12-19 DK DK16816667.6T patent/DK3405471T3/en active
- 2016-12-19 UA UAA201808693A patent/UA123508C2/en unknown
- 2016-12-19 RU RU2018129308A patent/RU2743098C2/en active
- 2016-12-19 GE GEAP201614858A patent/GEP20207126B/en unknown
- 2016-12-19 EA EA201891622A patent/EA036932B1/en unknown
- 2016-12-19 CN CN201680080679.7A patent/CN108602841B/en active Active
- 2016-12-19 RS RS20191499A patent/RS59622B1/en unknown
-
2018
- 2018-07-10 SV SV2018005722A patent/SV2018005722A/en unknown
- 2018-07-11 IL IL260550A patent/IL260550B/en active IP Right Grant
- 2018-07-12 PH PH12018501506A patent/PH12018501506A1/en unknown
- 2018-07-13 CL CL2018001908A patent/CL2018001908A1/en unknown
- 2018-07-16 CO CONC2018/0007443A patent/CO2018007443A2/en unknown
- 2018-07-17 ZA ZA2018/04770A patent/ZA201804770B/en unknown
- 2018-07-17 NI NI201800076A patent/NI201800076A/en unknown
- 2018-07-17 EC ECSENADI201853634A patent/ECSP18053634A/en unknown
- 2018-07-19 SA SA518392049A patent/SA518392049B1/en unknown
-
2019
- 2019-11-19 HR HRP20192073TT patent/HRP20192073T1/en unknown
-
2020
- 2020-01-27 CY CY20201100072T patent/CY1122560T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805913QA (en) | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201810576QA (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201810629QA (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |